biobusiness, drug development, biotech
How Orphan Drugs Became a Highly Profitable Industry
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Bioengineers Use Yeast to Manufacture Drugs
Bioengineers Use Yeast to Manufacture Drugs
Jim Daley | Apr 3, 2018
The yeast’s output of noscapine, a cough suppressant naturally made by poppies, is 18,000-fold higher than previous attempts.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Researchers Getting Smarter About Pairing Cancer Treatments
Researchers Getting Smarter About Pairing Cancer Treatments
Anna Azvolinsky | Apr 1, 2018
Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.
Infographic: Cancer Drug Pairings
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
SEC Charges Theranos With Fraud
SEC Charges Theranos With Fraud
Jim Daley | Mar 14, 2018
The company raised more than $700 million based on false claims to investors, according to the complaint.
How to Successfully Collaborate with Industry
How to Successfully Collaborate with Industry
Ashley P. Taylor | Mar 1, 2018
In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.
Flu Drug Approved in Japan Claims to Stop Virus in 24 Hours
Flu Drug Approved in Japan Claims to Stop Virus in 24 Hours
Kerry Grens | Feb 26, 2018
One dose of the medication, called Xofluza, cripples influenza by interfering with an enzyme critical for viral replication.  
Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals
Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals
Jim Daley | Jan 31, 2018
Biotech stocks fell in response to the news. 
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.